A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 07 2019
Historique:
received: 14 09 2018
revised: 29 01 2019
accepted: 15 04 2019
pubmed: 21 4 2019
medline: 23 9 2020
entrez: 21 4 2019
Statut: ppublish

Résumé

Four consensus molecular subtypes (CMS1-4) of colorectal cancer were identified in primary tumors and found to be associated with distinctive biological features and clinical outcomes. Given that distant metastasis largely accounts for colorectal cancer-related mortality, we examined the molecular and clinical attributes of CMS in metastatic colorectal cancer (mCRC). We developed a colorectal cancer-focused NanoString-based CMS classifier that is ideally suited to interrogate archival tissues. We successfully used this panel in the CMS classification of formalin-fixed paraffin-embedded (FFPE) tissues from mCRC cohorts, one of which is composed of paired primary tumors and metastases. Finally, we developed novel mouse implantation models to enable modeling of colorectal cancer Using our classifier, we find that the biological hallmarks of mCRC, including CMS, are in general highly similar to those observed in nonmetastatic early-stage disease. Importantly, our data demonstrate that CMS1 has the worst outcome in relapsed disease, compared with other CMS. Assigning CMS to primary tumors and their matched metastases reveals mostly concordant subtypes between primary and metastasis. Molecular analysis of matched discordant pairs reveals differences in stromal composition at each site. The development of two novel We describe the utility of a NanoString panel for CMS classification of FFPE clinical samples. Our work reveals the impact of intrinsic and extrinsic factors on colorectal cancer heterogeneity during disease progression.

Identifiants

pubmed: 31004000
pii: 1078-0432.CCR-18-3032
doi: 10.1158/1078-0432.CCR-18-3032
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4431-4442

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Robert Piskol (R)

Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, California. desousaf@gene.com omarkabbarah@gmail.com.

Ling Huw (L)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. desousaf@gene.com omarkabbarah@gmail.com.

Ismail Sergin (I)

Molecular Oncology, Genentech, Inc., South San Francisco, California.

Christiaan Kljin (C)

Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, California.

Zora Modrusan (Z)

Molecular Biology, Genentech, Inc., South San Francisco, California.

Doris Kim (D)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.

Noelyn Kljavin (N)

Molecular Oncology, Genentech, Inc., South San Francisco, California.

Rachel Tam (R)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.

Rajesh Patel (R)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.

Jeremy Burton (J)

Molecular Oncology, Genentech, Inc., South San Francisco, California.

Elicia Penuel (E)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.

Xueping Qu (X)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.

Hartmut Koeppen (H)

Pathology, Genentech, Inc., South San Francisco, California.

Teiko Sumiyoshi (T)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.

Frederic de Sauvage (F)

Molecular Biology, Genentech, Inc., South San Francisco, California.

Mark R Lackner (MR)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.

Felipe de Sousa E Melo (F)

Discovery Oncology, Genentech, Inc., South San Francisco, California. desousaf@gene.com omarkabbarah@gmail.com.

Omar Kabbarah (O)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH